Health Care • Medical/Dental Instruments
$2.77 ▼ -0.05
(-1.77%)
MKT CAP: $45.6M • VOL: 17.6K
52W L $3 52W H $5
SRTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $27.5M | $41.8M | $24.4M |
| YoY Revenue Growth % | -34.3% | +71.3% | — |
| Gross Profit | $11.9M | $24.4M | — |
| Gross Margin % | 43.2% | 58.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.3M | $8.1M | -$382.0K |
| Operating Margin % | -37.5% | 19.4% | -1.6% |
| Net Income (GAAP) | -$7.7M | $6.6M | $485.0K |
| EBITDA (Normalized) | -$10.2M | $8.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $528.0K | -$831.0K | -$2.1M |
| Capital Expenditures (CapEx) | $196.0K | $276.0K | — |
| Free Cash Flow (FCF) | $332.0K | -$1.1M | -$2.1M |
| FCF Margin % | 1.2% | -2.6% | -8.8% |
| Return on Invested Capital (ROIC %) | -31.3% | 18.9% | — |
| Cash & Short-Term Equivalents | $22.1M | $22.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $48.1M | $55.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SRTS.